Abbott or GE – who is smarter?

I am not a buyer of Abbott Labs (ABT) at this price, as the margin of safety has been depleted by the latest stock appreciation.  But I like its latest transaction with General Electric (NYSE GE).

Abbott or GE – who is smarter

I am not a buyer of Abbott Labs (ABT) at this price, as the margin of safety has been depleted by the latest stock appreciation.  But I like its latest transaction with General Electric (NYSE GE). Abbott proved to be a shrewd buyer and seller.  It played Johnson & Johnson (JNJ), Guidant (GDT) and Boston Scientific (BSX) masterfully and positioned themselves to be the “stealth” winner any way that the JNJ/Guidant or Boston Scientific/Guidant acquisition turned.

Diagnostic segment that Abbott is selling to GE for $8.5 billion generates revenues of $2.5 billion and has a 10% EBIT margin, putting a multiple of 34 times operating profits – that’s a nice fat premium – very smart on Abbott’s part.  In GE’s defense, it could probably drive some costs out of this business once it combines it with the rest of its medical business.

Please read the following important disclosure here.

Related Articles

From Bull to Sideways Markets to Nvidia

I discussed my condensed views on the stock market, economy, and our investment strategy in a letter to IMA clients.

Traditions, Investment Conferences and Presentations

Investment conferences are the constants in my life. This year, we heard 24 presentations in three days at VALUEx Vail.
The Slippery Slope of Student Loan Forgiveness

The Slippery Slope of Student Loan Forgiveness – Edition 2024

My daughter Hannah was just accepted to University of Denver. She might take out student loans. Why wouldn’t she?
Hedging the Portfolio with Weapons of Mass Destruction

Hedging the Portfolio with Weapons of Mass Destruction

Uber's business is doing extremely well. It has reached escape velocity – the company's expenses have grown at a slow rate while its revenues are growing at 22% a year.

Leave a Comment